Categories
Archives
Receive Email Updates
-
-
Certified Licensing Professionals, Inc., 2021 Disclaimer
This blog, Patents4Life, does not contain legal advice and is for informational purposes only. Its publication does not create an attorney-client relationship nor is it a solicitation for business. This is the personal blog of Warren Woessner and does not reflect the views of Schwegman Lundberg & Woessner, or any of its attorneys or staff. To the best of his ability, the Author provides current and accurate information at the time of each post, however, readers should check for current information and accuracy.
- About Me
Warren D. Woessner Pages
Archives
Tag Archives: Hatch-Waxman
Trump Signs Economic and Trade Agreement with China
On January 15, 2020, President Trump signed a lengthy “Economic and Trade Agreement Between the Government of the [US] and the Government of [P. R. of China].” Chapter 1 is entitled “Intellectual Property” that contains Sections on trade secrets, pharmaceuticals, … Continue reading
Cutting Through the Patent Thicket – The Little Bill that Couldn’t
A bill was recently proposed to “reduce the improper issuance of patents that improperly extend the term of exclusivity afforded a new drug or biological product.” The bill would amend the patent statutes (s. 253 or title 35) for add … Continue reading
Posted in Drug Patent Term
Tagged Drug Patent Term, Federal Circuit, Generic Drugs, Hatch-Waxman, orange book, PTAB
Leave a comment
Is the “Blocking Patent” Doctrine Part of the Obviousness Analysis?
Last year, in a lengthy split decision, a Fed. Cir. panel affirmed the district court’s ruling that four “add-on” patents that Acorda owned were invalid as obviousness in view of a number of prior art references (Acorda Ther., Inc. v. … Continue reading
Posted in Section 103
Tagged Acorda Therapeutics, Ampyra, FDA, Hatch-Waxman, judge dyk, Judge Taranto, Merck v Teva, Roxanne Labs, Supreme Court
Leave a comment